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1. Introduction 
Lafora disease or Lafora progressive myoclonic epilepsy was first described in 1911 by 
Gonzalo Lafora (Lafora, 1911; Lafora & Glueck, 1911). The disease belongs 
phenomenologically to the progressive myoclonic epilepsies (Monaghan & Delanty, 2010) 
and is the most prevalent of such conditions, which include myoclonic epilepsy with 
ragged-red fibers, action myoclonus-renal failure syndrome, Kuf’s disease, infantile 
neuroaxonal dystrophy, the sialidoses and Unverricht-Lundborg disease (Baltic myoclonus) 
(Monaghan & Delanty, 2010). These diseases afflict initially healthy children with ever-
worsening and soon intractable myoclonus and epilepsy, usually associated with 
neurodegeneration, eventual dementia and early death (Ramachandran et al., 2009). 
The first symptoms of Lafora disease appear between the ages of 8 and 18 years. There is an 
insidious, near-simultaneous or rapidly successive onset of headaches, difficulties in school 
work, myoclonic jerks, generalized seizures and in many cases, visual hallucinations of both 
epileptic and psychotic origin. The myoclonus, seizures and hallucinations gradually 
worsen and become intractable. For many years, the patient struggles to maintain normal 
contact and communication, interrupted by extremely frequent myoclonic absence seizures. 
Gradually, dementia sets in, and by 10 years after onset, the patient is in near continuous 
myoclonus with absences, frequent generalized seizures, and profound dementia or a 
vegetative state (Minassian, 2001; Ramachandran et al., 2009; Striano et al., 2008). 
A distinctive pathology characterizes Lafora disease. Cells of various types exhibit dense 
accumulations of malformed and insoluble glycogen molecules, termed polyglucosans, 
which lack the symmetric branching that allows glycogen to be soluble. These polyglucosan 
accumulations are called Lafora bodies, and in the central nervous system, they are present 
profusely in all brain regions and in the majority of neurons, specifically in the cell bodies 
and dendrites (Minassian, 2001; Ramachandran et al., 2009; Striano et al., 2008). 
Genetically, Lafora disease is an autosomal recessive disease caused by mutations in two 
genes: (1) the EPM2A gene, located on chromosome 6 at 6q24, coding for the protein laforin, 
a dual-specificity phosphatase (DSP), accounting for the largest group of patients (Minassian 
et al., 1998) and (2) the EPM2B (NHLRC1) gene, located on chromosome 6 at 6p22, coding 
for the protein malin, an E3 ubiquitin ligase that interacts with laforin (Chan et al., 2003a; 
Chan et al., 2003b). About 20% of cases are not explained by abnormalities in genes coding 
for laforin or malin (Singh & Ganesh, 2009); it is postulated that the mutations involved in 
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these cases involve either an unknown third gene or a regulatory sequence for the EPM2A 
or EPM2B genes (Monaghan & Delanty, 2010; Singh & Ganesh, 2009). 
Laforin is the only human DSP known to have a carbohydrate binding module (CBM) 
responsible for targeting the phosphatase towards glycogen (Wang et al., 2002). CBMs are 
typically found in glucosyl hydrolases and glucotransferases in bacterial, fungal or plant 
genomes (Boraston et al., 2000; Boraston et al., 2004; Gentry & Pace, 2009; Hashimoto, 2006; 
Shoseyov et al., 2006). The vast majority of enzymes containing CBMs utilize the domain to 
bind a specific glucan and enzymatically act on the sugar, as in the case of ǂ-amylase 
(Boraston et al., 2004). Accordingly, it has been demonstrated that laforin and starch excess 4 
protein (SEX4), an Arabidopsis thaliana protein with laforin-like properties (Gentry et al., 
2007), bind and dephosphorylate glucans, such as glycogen and starch (Gentry et al., 2007; 
Gentry et al., 2005; Tagliabracci et al., 2007; Tagliabracci et al., 2008; Tagliabracci et al., 2011; 
Worby et al., 2006). While laforin and SEX4 bind similar types of glucans, they utilize 
distinct CBMs (Boraston et al., 2004). CBMs are classified into 62 evolutionarily distinct 
families, based on their primary sequence, secondary and tertiary structure predictions, and 
crystal structures (Boraston et al., 2004; Hashimoto, 2006; Shoseyov et al., 2006). In 2004, 
laforin was included in the CBM20 family, formerly known as the starch-binding domain of 
family 4 – SBD4 (CAZy database - http://www.cazy.org/Carbohydrate-Binding-
Modules.html) (Coutinho & Henrissat, 1999). At that time, CBM20 family members were 
only known to be associated with amylases and glucanotransferases in bacteria, fungi and 
plants (Coutinho & Henrissat, 1999). The degree of homology of laforin and other members 
of the CBM20 family is very low. Furthermore, the laforin CBM secondary structure does 
not correlate very well with the other members of the CBM20 family (Girard et al., 2006). 
Nevertheless, the conservation of three tryptophans is of particular significance. They are 
invariant both in the few available laforin sequences from other species, as well as in most 
other CBM20 sequences (Girard et al., 2006). 
The phosphatase domain of laforin has been characterized and shown to act as a DSP, based 
on the differential kinetic parameters of dephosphorylation of the substrates p-nitrophenyl 
phosphate (pNPP) and 3-O-methylfluoresceinyl phosphate (OMFP). For DSPs, the kcat/KM 
values are typically more than two orders of magnitude higher with OMFP than with pNPP, 
whereas they are in the same order of magnitude for protein tyrosine phosphatases (Girard 
et al., 2006). 
The pNPPase activity of laforin has been shown to be inhibited by glycogen and related 
polysaccharides such as amylopectin and amylose, with inhibition potencies increasing with 
the decrease in polymer branching (Wang & Roach, 2004). Later, it was observed that laforin 
can dephosphorylate such polysaccharides (Tagliabracci et al., 2007). 
Laforin activity was also shown to be dependent on laforin dimerization via its CBM (Liu et 
al., 2006) and to interact with proteins involved in glycogen metabolism, such as glycogen 
synthase (GS) (Worby et al., 2006), and with the glycogen-targeting regulatory subunit R5 of 
protein phosphatase 1 (PP1) (Fernández-Sánchez et al., 2003). Laforin was also shown to 
interact with two ubiquitous proteins with unknown functions, EPM2AIP1 (Ianzano, 2003) 
and HIRIP5, a cytosolic protein predicted to be involved in iron homeostasis (Ganesh et al., 
2003). Laforin also interacts with malin, a single subunit E3 ubiquitin ligase containing a RING 
domain and six NHL domains (Gentry et al., 2005). Malin was shown to interact and to 
regulate laforin levels by mediating its ubiquitination, and the malin RING domain was 
necessary and sufficient to mediate laforin polyubiquitination leading to its proteosomal 
degradation (Gentry et al., 2005). Additionally, laforin was shown to recruit specific substrates 
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to be ubiquitinated by malin (Lohi et al., 2005; Solaz-Fuster et al., 2008). GS and R5 
ubiquitination promote the proteasomal degradation of both proteins (Lohi et al., 2005; Solaz-
Fuster et al., 2008), and K63-linked ubiquitination of AMP-activated protein kinase (AMPK, a 
serine/threonine protein kinase that acts as a sensor of the cellular energy status) which 
extends the protein lifetime (Moreno et al., 2010). Laforin also promotes the dephosphorylation 
of glycogen synthase kinase 3 (GSK3) at Ser9, activating this enzyme and leading to the GS 
phosphorylation at multiple sites with subsequent inhibition (Lohi et al., 2005). 
Therefore, laforin seems to be involved in glycogen metabolism as a sensor of poorly 
branched glycogen resulting from GS overactivity relative to glycogen-branching enzyme 
activity by modulating GS, either via GSK3 dephosphorylation resulting in GS inhibition, or 
via malin interaction, resulting in GS ubiquitination and subsequent degradation and 
inhibition of R5-induced glycogen synthesis. 
The laforin/malin complex has also been recently implicated in autophagy, acting as a 
cellular toxicity suppressor by clearing misfolded proteins through the proteasome system 
(Aguado et al., 2010; Garyali et al., 2009; Knecht et al., 2010). A putative role for laforin in 
Tau hyperphosphorylation (one of the distinctive hallmarks of Alzheimer’s disease) via 
GSK3 dephosphorylation has also been reported (Puri et al., 2009). 
Despite the solid evidence for laforin’s involvement in glycogen metabolism and Lafora 
disease, little is known about the structural mechanism of the glycogen interaction. This is due 
to the lack of a solid protocol for producing the large amounts of protein needed for structural 
studies. In this work we report the expression, purification and characterization of both laforin 
and its CBM, with appropriate yields for future structural and biophysical studies. 
2. Heterologous protein expression and purification 
In order to produce enough protein to perform structural studies, heterologous systems 
must be used. E. coli is by far the most widely employed host for heterologous protein 
expression (Rai & Padh, 2001). Its popularity is due to the vast body of knowledge about its 
genetics, physiology and complete genomic sequence, which greatly facilitates gene cloning 
and cultivation (Rai & Padh, 2001). High growth rates combined with the ability to express 
high levels of heterologous proteins, i.e., strains producing up to 30% of their total protein as 
the expressed gene product, result in high volumetric productivity. Furthermore, E. coli can 
grow rapidly to high densities in simple and inexpensive media (Rai & Padh, 2001).  
Laforin cDNA, coding for full-length laforin with a hexahistidine tag at its C-terminus, 
was cloned into the vector pET21a by Dr. Jack Dixon’s laboratory (Gentry et al., 2005). 
Previously, this tag was associated with problems in laforin purification and stability 
(Girard et al., 2006; Liu et al., 2006; Wang & Roach, 2004). Therefore, the hexahistidine tag 
was removed by using site-directed mutagenesis to introduce a stop codon at the end of 
the full-length laforin coding sequence. This was achieved using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions and 
using the oligonucleotide primers Laf_ΔHis-for and Laf_ΔHis-rev, whose sequences are 
presented in Table 1. 
The isolated CBM of laforin (Fig. 1, bold sequence) was also produced in order to study 
the biophysical interaction between the laforin CBM and carbohydrates and for future 
biotechnology applications. The cDNA sequence of the CBM domain was PCR amplified 
from the construct provided by Dr. Jack Dixon, using the oligonucleotides Laf_CBM-for 
and Laf_CBM-rev (Table 1), containing the restriction endonuclease recognition sites for 
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NcoI and XhoI, respectively, and ligated into NcoI/XhoI linearized pET29a. The 
Laf_CBM-rev primer introduced a RGD motif followed by a hexahistidine tag at the C-
terminus of the CBM. The RGD motif is found in the extracellular matrix and blood 
proteins, such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, 
fibrinogen, and von Willebrand factor and has been described as the major functional 
group responsible for cellular adhesion (Hwang et al., 2007; Ruoslahti & Pierschbacher, 
1987). The inclusion of a RGD motif at the C-terminus of the laforin CBM was intended to 
be a cell attachment motif in starch-based biomaterial functionalized with the CBM-RGD 
protein (Moreira et al., 2010). 
 
Primer name Primer sequence 
Laf_ΔHis-for CGTTCTTCTGTGTGTAGCCTGTGAGAGCACCACCACCACCACCAC 
Laf_ΔHis-rev GTGGTGGTGGTGGTGGTGCTCTCACAGGCTACACACAGAAGAACG 
Laf_CBM-for CATGCCATGGGGATGCGCTTCCGCTTTGGGG 
Laf_CBM-rev CCGCTCGAGATCACCTCTCATGGTTGGTGGCCTGC 
Table 1. Oligonucleotide primers used for laforin site-directed mutagenesis and for CBM 
cloning. The stop codon sequence introduced by site-directed mutagenesis is highlighted in 
bold. Underlined nucleotides indicate the restriction endonuclease recognition sequences 
used for cloning. 
Full-length Laforin and its CBM were expressed by transforming competent E. coli BL21 star 
strain (Invitrogen; a bacterial strain that is suited for high-level recombinant protein 
expression, due to improved stability of mRNA and the absence of lon and ompT proteases) 
with the constructs described above. After transformation, cells were plated onto Luria 
Broth (LB)-agar plates containing the appropriate antibiotic for positive clone selection, and 
positive colonies were then grown overnight in liquid LB/antibiotic media. These cultures 
were used to seed typically 1-2 liters of LB/antibiotic and grown at 37 ºC until the bacterial 
culture reached a cell density corresponding to an OD600 of 0.6. At that point, protein 
expression was induced for 3 h by the addition of isopropyl ǃ-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.5 mM.  
As previously reported, laforin expression in E. coli is associated with the appearance of 
inclusion bodies (Girard et al., 2006), with the CBM behaving in a similar way (Moreira et 
al., 2010). Our expertise in refolding proteins expressed in the form of inclusion bodies was 
crucial for the successful production of high amounts of correctly folded protein 
(Castanheira et al., 2005; Turner et al., 2001; Simões et al., 2007). After cell pellet disruption, 
the inclusion bodies were washed in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, followed by a 
second washing step in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, 0.1% Triton X-100 (v/v). 
These washing steps were needed to remove membrane proteins and other contaminants 
that are released upon cell disruption (Clark, 2001). Purified inclusion bodies were dissolved 
in 8 M urea buffer (8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, pH 10.5) with 100 mM 
ǃ-mercaptoethanol. 
Protein refolding was promoted by rapid dilution (20x) of the dissolved protein into 1 L of 
20 mM Tris base, 0.5 mM oxidized/1.25 mM reduced glutathione, 0.5 mM DTT; the pH was 
then slowly adjusted to pH 8.0 with 6 M HCl solution, and the protein was kept at 4 ºC until 
purification. After 3-7 days in a cold room, the refolded proteins were purified by two 
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 1  atgcgcttccgctttggggtggtggtgccacccgccgtggccggcgcccggccggagctg 
   M R F R F G V V V P P A V A G A R P E L  
 61  ctggtggtggggtcgcggcccgagctggggcgttgggagccgcgcggtgccgtccgcctg 
   L V V G S R P E L G R W E P R G A V R L  
 121 aggccggccggcaccgcggcgggcgacggggccctggccctgcaggagccgggcctgtgg 
   R P A G T A A G D G A L A L Q E P G L W  
 181 ctcggggaggtggagctggcggccgaggaggcggcgcaggacggggcggagccgggccgc 
   L G E V E L A A E E A A Q D G A E P G R  
 241 gtggacacgttctggtacaagttcctgaagcgggagccgggaggagagctctcctgggaa 
   V D T F W Y K F L K R E P G G E L S W E  
 301 ggcaatggacctcatcatgaccgttgctgtacttacaatgaaaacaacttggtggatggt 
   G N G P H H D R C C T Y N E N N L V D G  
 361 gtgtattgtctcccaataggacactggattgaggccactgggcacaccaatgaaatgaag 
   V Y C L P I G H W I E A T G H T N E M K  
 421 cacacaacagacttctattttaatattgcaggccaccaagccatgcattattcaagaatt 
   H T T D F Y F N I A G H Q A M H Y S R I  
 481 ctaccaaatatctggctgggtagctgccctcgtcaggtggaacatgtaaccatcaaactg 
   L P N I W L G S C P R Q V E H V T I K L  
 541 aagcatgaattggggattacagctgtaatgaatttccagactgaatgggatattgtacag 
   K H E L G I T A V M N F Q T E W D I V Q  
 601 aattcctcaggctgtaaccgctacccagagcccatgactccagacactatgattaaacta 
   N S S G C N R Y P E P M T P D T M I K L  
 661 tatagggaagaaggcttggcctacatctggatgccaacaccagatatgagcaccgaaggc 
   Y R E E G L A Y I W M P T P D M S T E G  
 721 cgagtacagatgctgccccaggcggtgtgcctgctgcatgcgctgctggagaagggacac 
   R V Q M L P Q A V C L L H A L L E K G H  
 781 atcgtgtacgtgcactgcaacgctggggtgggccgctccaccgcggctgtctgcggctgg 
   I V Y V H C N A G V G R S T A A V C G W   
 841 ctccagtatgtgatgggctggaatctgaggaaggtgcagtatttcctcatggccaagagg 
   L Q Y V M G W N L R K V Q Y F L M A K R  
 901 ccggctgtctacattgacgaagaggccttggcccgggcacaagaagattttttccagaaa 
   P A V Y I D E E A L A R A Q E D F F Q K  
 961 tttgggaaggttcgttcttctgtgtgtagcctgtga 
   F G K V R S S V C S L -  
Fig. 1. Laforin cDNA sequence (lower case letters) and translated protein sequence (upper 
case letters). The amino acids corresponding to the carbohydrate-binding module (CBM) are 
in bold.  
consecutive chromatographic steps. Each refolded protein was first concentrated to 150 mL 
by tangential flow ultrafiltration (Sartocon Slice, Sartorius), followed by concentration to 12-
15 mL with a N2-pressurized stirred-cell concentrator (Amicon 8200, Millipore). The protein 
solution was then clarified by ultracentrifugation (100,000x g, 20 min, 4 ºC), and the 
supernatant was applied to a size-exclusion chromatography column (HiLoad 26/60 
Superdex 200 prep grade, GE Healthcare), which was previously equilibrated in 20 mM Tris, 
0.4 M urea, pH 8.0, at 2 mL/min in order to separate the aggregated forms from the non-
aggregated forms of each protein (Fig. 2A and D). Full-length laforin (Fig. 2A) was shown to 
elute in two separate peaks. The first peak eluted at the expected column void volume 
(around 115 mL) and corresponded to soluble protein aggregates, and the second peak 
eluted at around 188 mL, which according to the column calibration should correspond to a 
globular protein with a molecular weight of 74 kDa, the expected value for the full-length 
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laforin dimer (2 x 37 kDa). The fractions obtained during size-exclusion purification were 
analyzed for phosphatase activity in 50 mM Tris/HCl buffer, pH 7.2 at 30 ºC using 10 mM 
pNPP as the substrate by spectrophotometrically following the increase of absorbance at 410 
nm induced by the release of p-nitrophenol (ε410nm = 18.3 mM_1 cm_1) (Girard et al., 2006). 
The second peak from the size-exclusion was active. The active fractions were combined, 
and the protein was further purified by anion-exchange chromatography on a Mono Q 5/50 
GL (GE Healthcare) (Fig. 2B).  
 
 
Fig. 2. Protein purification. (A) Full-length laforin size-exclusion chromatogram; (B) 
Anion-exchange chromatogram of full-length laforin; (C) SDS-PAGE analysis of full-
length laforin purification: (1) E. coli cells before induction; (2) E. coli cells after a 3 h 
induction, soluble fraction; (3) cells after a 3 h induction, insoluble fraction; (4) 
concentrated protein applied to a size-exclusion column; (5) second peak from the size 
exclusion column applied to an anion-exchange column; (6) Anion-exchange major peak; 
(7) molecular weight standard. The gel was stained with Coomassie brilliant blue. (D) 
Laforin’s CBM size-exclusion chromatogram; (E) Anion-exchange chromatogram of 
laforin’s CBM; (F) SDS–PAGE analysis of laforin’s CBM purification: (1) sample applied to 
a size-exclusion column; (2) second peak (eluted at about 150–200 mL) from the size-
exclusion column; (3) highest peak (eluted at about 20 mL) from the anion-exchange 
column; (4) molecular weight standard. The gel was stained with Coomassie brilliant 
blue. 
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Step 
Volume 
(mL) 
Total 
Activity (U)
Total 
Protein (mg)
Specific 
Activity 
(U/mg) 
Yield 
(%) 
Purification 
Factor 
Refolded 7 7250 39 186 100  
Superdex 38 5524 22 251 56 1.3 
Mono Q 6.5 3400 7 486 47 2.6 
Table 2. Full-length laforin purification table. One unit of activity was defined as the activity 
corresponding to the consumption of 1 μM substrate (pNPP) in one minute at 30 ºC. 
Most of the protein was eluted in the major peak with a NaCl concentration of 
approximately 250 mM, which was also the peak where most of the pNPPase activity was 
found, indicating that most of the protein was correctly folded and relatively homogeneous. 
At the end of the purification process from several expression batches, we obtained between 
5 and 7 mg of purified laforin per liter of expression media. The purification table (Table 2) 
shows that the starting material after refolding was already relatively pure, as the 
purification factor was only 2.6, which is again consistent with the lack of contaminant 
bands in the SDS-PAGE profile of the refolded protein (Fig. 2C, lane 3). 
 
Step 
Total 
Protein 
(mg) 
Estimated 
amount of total 
CBM (mg) 
Yield (%) Purity (%) 
Cell extract 306 85.7 100 28 
Refolded protein 106 72.1 84 68 
Applied to size 
exclusion 
43.4 34.7 40 80 
Applied to ion 
exchange 
33 29.7 35 90 
Mono Q (major peak) 12.8 11.5 13 90 
Table 3. Laforin CBM purification table. Purity was determined by analysis of SDS–PAGE 
band intensities using the Quantity One software, version 4.6 (BioRad). 
For the CBM of laforin, a similar procedure was adopted. The first purification step, by size-
exclusion chromatography (HiLoad 26/60 Superdex 200 prep grade, GE Healthcare), was 
run with the same conditions as for the full-length protein and revealed no significant 
aggregates. Most of the protein eluted at 173 mL, which corresponds to tetrameric laforin 
CBM, and a minor fraction that eluted at 198 mL corresponds to dimerized protein (Fig. 2D). 
The fractions corresponding to the major peak were combined and applied to the anion 
exchange column (Mono Q 5/50 GL, GE Healthcare), with most of the protein eluted at 400 
mM NaCl (Fig. 2E). The SDS-PAGE analysis of the purified protein revealed an intense band 
with a molecular weight close to the expected value (22 kDa), and even under denaturing 
conditions, a band corresponding to the dimeric form of the protein was observed (Fig. 2F). 
This result is in agreement with the previously described resistance of laforin to dimer 
separation, prior to SDS–PAGE (Liu et al., 2006). 
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The purification table of laforin CBM purification shows a yield of more than 12 mg of 
purified protein per liter of expression media. This protein expression and purification 
method is the first successful strategy to obtain the laforin CBM and will thus allow its study 
and characterization as an independent unit, as well as its use in biotechnology applications 
(Moreira et al., 2010).  
3. Heterologous protein characterization 
3.1 Protein oligomerization state 
Laforin has been shown to exist in a dimeric state; the CBM is responsible for this 
dimerization because its deletion completely abolishes the dimerization and phosphatase 
activity of laforin (Liu et al., 2006). The oligomerization state of both laforin and its CBM 
were analyzed by two distinct methods: analytical size-exclusion chromatography and 
dynamic light scattering (DLS) (Fig. 3). 
 
 
Fig. 3. Protein oligomerization analysis. (A) Analytical size-exclusion chromatography of 
purified full-length laforin with a Superose 12 10/300 GL column (GE Healthcare); (B) 
Dynamic Light Scattering analysis of purified full-length laforin; (C) Analytical size-
exclusion chromatography of purified laforin CBM with a Superdex 200 10/300 GL column 
(GE Healthcare); (D) Dynamic Light Scattering analysis of purified laforin CBM. 
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The analysis of full-length laforin by analytical size-exclusion chromatography on Superose 
12 10/300 GL confirmed that laforin is highly homogeneous, eluting with an elution volume 
corresponding to a globular protein of 64 kDa, based on the column calibration (Fig. 3A, 
grey box). This result is consistent with the dimer state of full-length laforin (2 x 37 kDa). 
This result was later confirmed by DLS. The protein was analyzed in both the anion-
exchange elution buffer (20 mM Tris, 0.4 M urea, 250 mM NaCl, pH 8.0) and in 50 mM Tris, 
50 mM NaCl, pH 7.4, with similar results. The particles detected had a hydrodynamic radius 
corresponding to a globular protein with a mass of 76 kDa, again consistent with the 
presence of a dimer. 
The analysis of the oligomerization state of the CBM of laforin by analytical size-exclusion 
chromatography using a Superdex 200 10/300 GL showed that the protein is also in a 
dimeric state, with a calculated molecular weight of 44 kDa. The differences observed 
between the preparative size-exclusion chromatography used during protein purification, 
where the protein eluted as a tetramer, and the analytical size-exclusion chromatography, 
where the protein eluted as a dimer, are due to the presence of 150 mM NaCl in the 
analytical size-exclusion chromatography buffer, which was absent from the preparative 
size exclusion chromatography buffer. The DLS analysis confirmed this result; the protein 
eluting in the highest peak from the anion-exchange column (Fig. 2E) revealed a 
hydrodynamic radius corresponding to a 44 kDa protein, thus confirming the dimerization 
of the isolated protein. 
3.2 Protein – carbohydrate interaction assay 
The functionality of the CBM, i.e., its ability to bind starch, was evaluated using an 
adsorption assay, for both the full-length laforin and for the CBM. The purified protein 
samples were centrifuged (13,000 rpm, 10 min, 4 ºC) to remove any precipitated protein, and 
the protein was then mixed with 50 mg of starch (previously washed with 50 mM Tris–HCl, 
150 mM NaCl, pH 7.4 buffer) for 1 h at 4 ºC. The mixture was centrifuged (13,000 rpm, 10 
min, 4 ºC), and the supernatant was analyzed by SDS–PAGE. The starch was washed with 
buffer (3 x 0.3 mL), and the recombinant protein was eluted from the starch with a 5 mg/mL 
glycogen solution (0.3 mL, at 4 ºC for 1 h). The starch was then treated with buffer 
containing 2% SDS (0.3 mL, at 95 ºC for 5 min) in order to analyze the protein that remained 
adsorbed after glycogen elution. 
The results showed that both full-length laforin and its CBM are able to bind starch and are 
specifically desorbed from starch when incubated with glycogen. For the full-length laforin, 
the SDS-PAGE analysis (Fig. 4A) revealed that most of the protein binds to the starch moiety 
because the protein solution supernatant after starch incubation (Fig. 4A lanes 2) showed a 
significant decrease in protein levels. This is not due to precipitated protein in the sample 
because the protein sample was centrifuged prior to the starch incubation. The subsequent 
washing steps revealed no washed protein (Fig. 4A lanes 3), and after the incubation with 
glycogen, laforin was effectively eluted from starch (Fig. 4A, lane 4). From the differences in 
band intensities between the initial protein and the supernatant after incubation, one would 
expect a stronger band from the glycogen elution, but the relatively faint band resulting 
from the glycogen elution can be attributed to a stronger binding of laforin to starch rather 
than glycogen, as previously reported (Chan et al., 2004). The results obtained with the CBM 
are in line with this assumption because a stronger protein band is observed in the starch 
pellet after glycogen elution (Fig. 4B, lane 4) than the one resulting from the glycogen 
elution (Fig. 4B, lane 3). 
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Fig. 4. Protein–starch-binding assay. (A) Full-length laforin starch-binding assay: (1) laforin 
supernatant before starch incubation; (2) supernatant after starch incubation; (3) starch-
washing supernatant; (4) supernatant after glycogen elution. All steps were performed in 
duplicate. Gel was silver stained. (B) CBM starch-binding assay: (1) CBM supernatant before 
starch incubation; (2) starch-washing supernatant; (3) supernatant after glycogen elution; (4) 
starch pellet after glycogen elution. All steps were performed in duplicate. The gel was 
Coomasie stained. 
Together, these results confirmed the starch binding activity of both laforin and its CBM. 
3.3 Laforin phosphatase activity characterization 
The laforin phosphatase activity was characterized using both pNPP (Montalibet et al., 2005) 
and OMFP, previously reported to be a better substrate for dual-specificity phosphatases 
than pNPP (Girard et al., 2006; Gottlin et al., 1996). The kinetic parameters for pNPP as a 
substrate were measured in a total volume of 1 mL by incubation of the enzyme with 
various amounts of substrate in 50 mM Tris-HCl buffer, pH 7.2 in a Varian Cary 100 UV/Vis 
spectrophotometer with the temperature control set to 30 ºC by following the absorbance 
increase at 410 nm induced by the release of p-nitrophenol (ε410nm = 18.3 mM-1 cm-1) (Girard 
et al., 2006). For OMFP, the kinetic parameters were obtained by a fluorescence-based assay, 
using conditions similar to the ones used for pNPP. The assay was performed using a 
Horiba Jobin Yvon Fluoromax-3 fluorometer by following the fluorescence emission of the 
product formed with excitation at 485 nm and emission measured at 530 nm. The data were 
fit to the Michaelis-Menten equation (Eq. 1) using the software Enzyme Kinetics Module 
v.1.2 – Sigmaplot v 9.01 (Systat Software, Inc.).  
 V = kcat [S] / (KM + [S])       (1) 
The kinetic parameters (Table 4) show that the recombinant laforin produced in this study 
has similar properties when compared to the previously published kinetic parameters for 
GST- and His-tagged versions of laforin (Girard et al., 2006), confirming the behavior of 
laforin as a dual-specificity phosphatase with OMFP better as the substrate than pNPP 
(Castanheira et al., 2010).  
The pH profile of laforin phosphatase activity was also evaluated using OMFP as a 
substrate. The results presented in Fig. 5A are in agreement with the results published 
earlier for tagged versions of laforin (Girard et al., 2006; Peters et al., 2003; Wang et al., 2002; 
Wang & Roach, 2004), with maximal activity at the acidic pH of 6.0. The capability of 
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glycogen to inhibit the phosphatase activity of laforin was also evaluated by including 
increasing amounts of glycogen in the phosphatase activity assay. The results presented in 
Fig. 5B show that laforin, in agreement with previously published reports (Girard et al., 
2006; Wang & Roach, 2004), is effectively inhibited by glycogen with an AC50 of around 50 
μg/mL. 
 
Enzyme 
pNPP  OMFP  
kcat (s-1) KM (mM)
kcat/KM 
(s-1.mM-1) 
 kcat (s-1) KM (mM)
kcat/KM 
(s-1.mM-1) 
Laforin 0.56 ± 0.07 8.4 ± 0.7 0.07 ± 0.01  7.6 ± 1.5 0.21 ± 0.05 36 ± 11 
GST-pG 
laforin 
1.1 ± 0.1 11.4 ± 3.0 0.10 ± 0.03  9.5 ± 2.0 0.26 ± 0.04 36 ± 13 
His-laforin 1.7 ± 0.2 33 ± 3 0.051 ± 0.004  6.5 ± 1.3 0.75 ± 0.29 8.7 ± 5.1 
Table 4. Steady-state kinetic parameters for laforin phosphatase activity. Comparison with 
published data for tagged versions of laforin, obtained from Girard (2006). 
 
 
Fig. 5. Laforin phosphatase activity characterization: Optimum pH (A) and inhibition by 
glycogen (B).  
4. Conclusion 
In this work, we have shown that both full-length laforin and its CBM can be produced in E. 
coli expression systems in high amounts and purified without the use of fusion tags. The 
characterization of the purified protein showed that in both cases, the protein is dimerized 
and has a functional CBM. For full-length laforin, the phosphatase activity was 
characterized and shown to have similar characteristics to the various forms of laforin 
previously described. The protein expression methodology used in this study proved to be 
suited for the production of high amounts of protein. This will enable the structural 
characterization and determination of the three-dimensional structure of laforin, which will 
contribute to the understanding of the molecular mechanism of action of laforin. The 
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understanding of both the mechanism of the laforin-laforin or laforin-malin interactions is 
important for the development of Lafora disease therapies. The protein-protein and protein-
carbohydrate interfaces represent targets for the design of new drugs that promote or 
stabilize laforin’s dimerization or its interaction with binding partners (Veselovsky et al., 
2002).  
5. Future perspectives 
The work presented in this chapter paves the way for the structural studies needed to 
understand the molecular mechanism of protein-carbohydrate interaction. These studies 
will be performed using techniques such as NMR that will provide site-specific information 
on the architecture, binding selectivity and plasticity of the carbohydrate-binding sites of 
laforin. Other biophysical techniques such as Trp fluorescence have been used to address 
the chemical polarity shifts associated with protein-carbohydrate interactions. Protein-
carbohydrate interactions will also be studied by surface plasmon resonance in order to 
obtain the kinetic parameters of carbohydrate-ligand binding with wild-type and mutant 
proteins. Finally, X-ray crystallography and solution NMR will be used to obtain the three 
dimensional structure of laforin and its CBM, respectively. 
These studies will most likely provide new insights into the molecular mechanism of 
protein-carbohydrate binding and into the structural determinants involved in laforin 
dimerization, which will create new opportunities for the design of Lafora disease therapies 
and novel biotechnology applications for carbohydrate-binding proteins. 
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